These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21209231)

  • 1. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects.
    Migoya E; Larson P; Bergman A; Miller J; Johnson-Levonas AO; Lasseter KC; Wagner JA
    J Clin Pharmacol; 2011 Sep; 51(9):1319-25. PubMed ID: 21209231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG; Dai Y
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
    Kasserra C; Li J; March B; O'Mara E
    Clin Ther; 2011 Oct; 33(10):1503-14. PubMed ID: 22015327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics.
    Schwartz JI; Dunbar S; Yuan J; Li S; Miller DL; Rosko K; Johnson-Levonas AO; Lasseter KC; Wagner JA
    J Clin Pharmacol; 2009 Jan; 49(1):72-9. PubMed ID: 18936284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive.
    Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C
    Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of sumatriptan when administered with norethindrone 1 mg/ethinyl estradiol 0.035 mg in healthy volunteers.
    Moore KH; McNeal S; Britto MR; Bye C; Sale M; Richardson MS
    Clin Ther; 2002 Nov; 24(11):1887-901. PubMed ID: 12501881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.
    Hendrix CW; Jackson KA; Whitmore E; Guidos A; Kretzer R; Liss CM; Shah LP; Khoo KC; McLane J; Trapnell CB
    Clin Pharmacol Ther; 2004 May; 75(5):464-75. PubMed ID: 15116059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
    Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
    Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
    Krishna R; Bergman A; Larson P; Cote J; Lasseter K; Dilzer S; Wang A; Zeng W; Chen L; Wagner J; Herman G
    J Clin Pharmacol; 2007 Feb; 47(2):165-74. PubMed ID: 17244767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
    Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
    Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
    Mistry GC; Bergman AJ; Luo WL; Cilissen C; Haazen W; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
    J Clin Pharmacol; 2007 Feb; 47(2):159-64. PubMed ID: 17244766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
    Mistry GC; Maes AL; Lasseter KC; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
    J Clin Pharmacol; 2008 May; 48(5):592-8. PubMed ID: 18353996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
    Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
    Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norethisterone and ethinyl estradiol kinetics during dapsone therapy.
    Joshi JV; Maitra A; Sankolli G; Bhatki S; Joshi UM
    J Assoc Physicians India; 1984 Feb; 32(2):191-3. PubMed ID: 6746515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women.
    Sekar VJ; Lefebvre E; Guzman SS; Felicione E; De Pauw M; Vangeneugden T; Hoetelmans RM
    Antivir Ther; 2008; 13(4):563-9. PubMed ID: 18672535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir.
    Garg V; van Heeswijk R; Yang Y; Kauffman R; Smith F; Adda N
    J Clin Pharmacol; 2012 Oct; 52(10):1574-83. PubMed ID: 22039291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.